In the latest quarter, 9 analysts provided ratings for Protagonist Therapeutics (NASDAQ:PTGX), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...
In March, the companies announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC). The study met its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results